免疫性血小板减少症(ITP)是一种较常见的免疫性疾病,主要发病机制是由于抗血小板自身抗体引起的血小板破坏并有血小板生成受限。ITP可发生于任何年龄,在儿童多数呈急性经过,自发缓解率高;而90%成人患者为慢性,其中15%对各种治疗不敏感。1 ITP治疗现状ITP患者在血小板计数明显降低特别是有出血倾向时都需要治疗,临床上一般分为一线治疗与二线治疗。一线治疗主要包括皮质激素与静脉注射免疫球蛋白(IVIg);二线治疗的方法在国内外有 Immune thrombocytopenia (ITP) is a more common immune disease, the main pathogenesis is due to anti-platelet autoantibodies caused by platelet destruction and platelet formation is limited. ITP can occur at any age, has a high rate of spontaneous remission in most children, and is chronic in 90% of adults, 15% of whom are insensitive to various therapies. 1 The status of ITP treatment ITP patients in the platelet count was significantly lower bleeding tendency in particular need to be treated when clinically generally divided into first-line treatment and second-line treatment. First-line treatment includes corticosteroids and intravenous immunoglobulin (IVIg); second-line treatment at home and abroad have